Compare · ORKA vs TKNO
ORKA vs TKNO
Side-by-side comparison of Oruka Therapeutics Inc. (ORKA) and Alpha Teknova Inc. (TKNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ORKA and TKNO operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $6.24B, about 16.9x TKNO ($369.4M).
- ORKA has hit the wire 10 times in the past 4 weeks while TKNO has been quiet.
- ORKA has more recent analyst coverage (11 ratings vs 9 for TKNO).
- Company
- Oruka Therapeutics Inc.
- Alpha Teknova Inc.
- Price
- -
- -
- Market cap
- $6.24B
- $369.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 10
- 0
- Recent ratings
- 11
- 9
Latest ORKA
- Chief Operating Officer Sandler Laura Lee exercised 5,000 shares at a strike of $7.80 and sold $459,101 worth of shares (5,000 units at $91.82) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Klein Lawrence Otto exercised 75,000 shares at a strike of $7.80 and sold $6,887,484 worth of shares (75,000 units at $91.83) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 424B5 filed by Oruka Therapeutics Inc.
- SEC Form EFFECT filed by Oruka Therapeutics Inc.
- Chief Commercial Officer Edwards Larry Todd was granted 100,000 shares (SEC Form 4)
- SEC Form 3 filed by new insider Edwards Larry Todd
- Oruka Therapeutics Inc. filed SEC Form 8-K: Leadership Update
- Oruka Therapeutics Appoints Todd Edwards as Chief Commercial Officer
- SEC Form S-3 filed by Oruka Therapeutics Inc.
- Chief Medical Officer Goncalves Joana exercised 7,000 shares at a strike of $7.32 and sold $782,882 worth of shares (7,000 units at $111.84) as part of a pre-agreed trading plan (SEC Form 4)
Latest TKNO
- Alpha Teknova upgraded by BTIG Research with a new price target
- SEC Form 10-Q filed by Alpha Teknova Inc.
- Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Teknova Reports Second Quarter 2026 Financial Results
- Teknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in Minutes
- Roth Capital initiated coverage on Alpha Teknova with a new price target
- Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026
- Director Demski Martha J disposed of 12,000 shares and acquired 12,000 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Vos Alexander
- SEC Form 4 filed by Director Robertson Brett